Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S
Authors:
- Azadeh ShoaibiASAzadeh Shoaibi
- Patricia C. LloydPLPatricia C. Lloyd
- Hui-Lee WongHWHui-Lee Wong
- Tainya C. ClarkeTainya C. Clarke
- Yoganand ChillarigeYCYoganand Chillarige
- Rose DoRDRose Do
- Mao HuMHMao Hu
- Yixin JiaoYJYixin Jiao
- Andrew KwistAKAndrew Kwist
- Arnstein LindaasALArnstein Lindaas
- Rowan McEvoyRMRowan McEvoy
- Michelle OndariMOMichelle Ondari
Preprint
Abstract
Background Our near-real-time safety monitoring of 16 adverse events (AEs) following COVID-19 mRNA vaccination identified potential elevations in risk for six AEs following primary series and monovalent booster dose administration. The crude association with AEs does not imply causality. Accordingly, we conducted robust evaluations of the potential associations. Methods We conducted self-controlled case series studies of COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) in U.S. Medicare beneficiaries aged 65 years and older. Adjusted incidence rate ratio (IRRs) and 95% confidence intervals (CIs) were estimated following primary series doses for acute myocardial infarction (AMI), pulmonary embolism (PE), immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC); and following booster doses for AMI, PE, ITP, Bell ‘s Palsy (BP) and Myocarditis/Pericarditis (Myo/Peri). Results Among 3,360,981 individuals who received 6,388,542 primary series doses and 6,156,100 individuals with monovalent booster doses of either BNT162b2 or mRNA-1273, AE counts were: AMI (3,653 primary series, 16,042 booster), inpatient PE (2,470 primary, 5,085 booster), ITP (1,085 primary, 88 booster), DIC (254 primary), BP (3,268 booster), and Myo/Peri (1,295 booster). The IRR for inpatient PE cases following BNT162b2 primary series and booster was 1.19 (95% CI: 1.03 to 1.38) and 0.86 (95% CI: 0.78 to 0.95), respectively; and for mRNA-1273 primary series and booster, 1.15 (95% CI: 0.94 to 1.41) and 0.87 (95% CI: 0.79 to 0.96), respectively. The IRR for BP following BNT162b2 and mRNA-1273 booster was 1.17 (95% CI: 1.06 to 1.29) and 1.16 (95% CI: 1.05 to 1.29), respectively. Conclusion In these two studies of the U.S. elderly we did not find an increased risk for AMI, ITP, DIC, and Myo/Peri; the results were not consistent for PE; and there was a small elevated risk of BP after exposure to COVID-19 mRNA vaccines. These results support the favorable safety profile of COVID-19 mRNA vaccines administered in the elderly. HIGHLIGHTS There was no increased risk for four of six outcomes following COVID-19 monovalent mRNA vaccines. There was a small elevated risk of Bell ‘s Palsy after exposure to COVID-19 monovalent mRNA vaccines. Risk of pulmonary embolism was not consistent after exposure to COVID-19 monovalent mRNA vaccines.Keywords
All Related Versions
- Published version: Vaccine, 41 (32), 4666.
This publication has 30 references indexed in Scilit:
- First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in ScotlandNature Medicine, 2021
- Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)Vaccine, 2021
- Association of Facial Paralysis With mRNA COVID-19 VaccinesJAMA Internal Medicine, 2021
- Immune Thrombocytopenia Secondary to COVID-19: a Systematic ReviewSN Comprehensive Clinical Medicine, 2020
- Pulmonary Embolism in Patients With COVID-19Circulation, 2020
- COVID-19 and Cardiovascular DiseaseCirculation, 2020
- Model-based estimation of the attributable risk: A loglinear approachComputational Statistics & Data Analysis, 2012
- Case series analysis for censored, perturbed, or curtailed post-event exposuresBiostatistics, 2008
- Multiple Imputation for Interval Estimation From Simple Random Samples With Ignorable NonresponseJournal of the American Statistical Association, 1986
- Probable Inference, the Law of Succession, and Statistical InferenceJournal of the American Statistical Association, 1927